Quanterix Corporation

What they do

Quanterix sells proprietary Simoa instruments, consumables, and assay kits, along with newly acquired Akoya spatial biology platforms, to research laboratories, CROs, academic institutions, and biopharma companies. Its Simoa technology detects protein biomarkers at femtomolar concentrations in blood, serum, and other fluids. It also runs contract research services and four Laboratory Developed Tests through its CLIA-certified Accelerator Laboratory in Bedford, Massachusetts. Reported installed base exceeds 2,500 instruments with citations in more than 6,200 scientific publications.

Revenue drivers

• Instruments and consumables — Core Simoa instrument and consumable sales to research labs, CROs, academic institutions, and biopharma; the installed base of over 2,500 instruments generates recurring consumables revenue as the base grows.
• Spatial biology (Akoya) — Akoya instrument platforms, reagents, software, and services for spatial phenotyping, acquired July 8, 2025, adding tissue-analysis revenue alongside the existing fluid-based Simoa business.
• Services and diagnostics — Contract research services and clinical laboratory testing, including four LDTs, through the CLIA-certified Accelerator Laboratory; over 2,600 projects completed for more than 500 customers.
• Beads and OEM segment (Emission) — Emission, acquired January 8, 2025, produces dye-encapsulating magnetic beads and a mid-plex platform, targeting third-party OEM customers and supporting next-generation Quanterix platforms.

Recent performance

Q2 2026 revenue was $32.9 million, up 34% from $24.5 million a year earlier. GAAP gross margin fell to 38.5% from 40.9%, while adjusted gross margin rose to 47.9% from 41.8%. Adjusted EBITDA loss was $10.0 million versus $13.7 million a year ago, and adjusted cash usage was $4.0 million, down $10.8 million from Q1 2026. The quarter included a $26.9 million goodwill impairment tied to the Akoya acquisition. Full-year revenue was $138.9 million in 2025 versus $137.4 million in 2024, with a 2025 net loss of $107.2 million.

Strategy

Management is integrating Akoya and Emission, having completed ERP integration in Q2 2026 and realizing $85 million in annualized savings from the Akoya program. It is reorganizing commercial teams and adding leadership, including a new Chief Commercial Officer, COO, CFO, and SVP/GM of Diagnostics. It is investing in Diagnostics, including Lucent Diagnostics, the four LDTs, and Alzheimer's disease testing, and submitted a 510(k) for a multi-analyte algorithmic Alzheimer's blood test on January 31, 2026. The stated goal is to return to sustained growth and reach cash flow breakeven, although the company revised its 2026 outlook and extended the breakeven target date.

Risks

• Persistent losses and cash burn — Quanterix has incurred annual net losses since inception, including $107.2 million in 2025, and operating cash flow was negative $77.2 million that year.
• Akoya integration and impairment — Integrating Akoya may be more costly or time-consuming than expected, and the company already recorded a $26.9 million goodwill impairment related to that acquisition in Q2 2026.
• Commercial execution and market softness — Q2 2026 revenue of $32.9 million fell short of expectations due to execution challenges and continued market softness, prompting a commercial reorganization.
• Diagnostics and reimbursement uncertainty — The company may not succeed in penetrating the diagnostics market, and its Alzheimer's blood test strategy depends on clinical utility studies and an FDA roadmap that are still in progress.

Outlook

Management revised its 2026 financial outlook and extended the date for reaching cash-flow breakeven, citing Q2 revenue shortfalls. It expects to incur operating losses into 2026 as it funds R&D, diagnostics initiatives, and regulatory submissions. The company points to strategic Diagnostics investments, three clinical utility studies, and an FDA roadmap for Alzheimer's testing as key milestones ahead.